Depot antipsychotic medication is a major component of the maintenance treatment of schizophrenia, but it is still not clear what constitutes an appropriate dose. A number of studies comparing low with standard doses of depot antipsychotic medication on a variety of outcome measures have been published in the last decade. A review of these studies indicates that, compared to standard-dose treatment, low-dose medication tends to improve psychosocial function and reduce the frequency of side effects but may result in an increase in positive symptoms. In such cases, a temporary increase in dose appears to control symptoms and terminate relapse episodes. An explanation of the relative efficacy of low-dose treatment may be derived from recent work in radioreceptor ligand binding.
No takes yet. Share an insight, caveat, or question.
Burnett et al. (1993) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: